SCHEMBL4680692

SCHEMBL4680692

O=C(O)C(O)=CC(=O)c1ccnn1Cc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.43
GPR52 Q9Y2T5 1/20 0.42
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
PTGS1 P23219 1/20 0.40
GRN P28799 2/20 0.39
SORT1 Q99523 2/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP19A1 P11511 1/20 0.39
HPGD P15428 1/20 0.38
POLB P06746 1/20 0.38
MARS1 P56192 1/20 0.38
FLT1 P17948 1/20 0.38
KDR P35968 1/20 0.38
HSD11B1 P28845 1/20 0.37
MALT1 Q9UDY8 1/20 0.37
ESR1 P03372 1/20 0.36
RECQL P46063 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4672871 0.90 KDM4E (0.46) MEN1KMT2AALDH1A1MARS1FLT1
SCHEMBL4679110 0.87 HTT (0.45) ALDH1A1
SCHEMBL4676024 0.87 KDM4E (0.38) P2RX7MEN1KMT2AALDH1A1HPGD
SCHEMBL4676695 0.87 SMN1; SMN2 (0.45) MEN1KMT2AALDH1A1CYP19A1POLB
SCHEMBL4672327 0.86 KDM5A (0.41) KMT2AALDH1A1
SCHEMBL4672631 0.85 P2RY14 (0.38) MEN1KMT2AALDH1A1HPGD
SCHEMBL4677605 0.85 MARS1 (0.44) MEN1KMT2AALDH1A1POLBMARS1
SCHEMBL4680080 0.84 NPBWR1 (0.47) CYP19A1
SCHEMBL4673966 0.84 KMT2A (0.40) MEN1KMT2AALDH1A1HPGD
SCHEMBL27676261 0.81 P2RX7 (0.50) P2RX7GPR52MEN1KMT2AGRN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 P2RX7 2593/4885GPR52 2542/4885MEN1 4663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.